0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > Carbonic Anhydrase IX

Carbonic Anhydrase IX

Carbonic Anhydrase IX Molecule Information

Name:Carbonic anhydrase IX
Target Synonym:EC:4.2.1.1,Renal cell carcinoma-associated antigen G250,P54/58N,CA9,Carbonic Anhydrase 9,RCC-Associated Protein G250,Carbonate Dehydratase IX,Carbonic Dehydratase,CA-IX,CAIX,PMW1,MN,EC 4.2.1.1,G250,Carbonic anhydrase IX,Membrane antigen MN,RCC-associated
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:4
Lastest Research Phase:Phase 2 Clinical

Carbonic Anhydrase IX Protein Product ListCompare or Buy

Carbonic Anhydrase IX Molecule Synonym Name

CAIX,CA9,CA-IX,G250,MN,P54/58N,pMW1

Carbonic Anhydrase IX Molecule Background

Carbonic anhydrases (CAs) are a large family of zinc metalloenzymes. CAs form a family of enzymes that catalyze the rapid interconversion of carbon dioxide and water to bicarbonate and protons (or vice versa), a reversible reaction that occurs rather slowly in the absence of a catalyst. One of the functions of the enzyme in animals is to interconvert carbon dioxide and bicarbonate to maintain acid-base balance in blood and other tissues, and to help transport carbon dioxide out of tissues. The active site of most carbonic anhydrases contains a zinc ion. There are at least five distinct CA families (α, β, γ, δ and ε). Carbonic anhydrase 9 (CA9 / CAIX) is also known as Membrane antigen MN (MN), Renal cell carcinoma-associated antigen G250, which belongs to the alpha-carbonic anhydrase family. CA9 / CAIX with an optimal activity at pH 6.49. Reversible hydration of carbon dioxide. CA IX participates in pH regulation. CA9 may be involved in the control of cell proliferation and transformation. CA-IX appears to be a novel specific biomarker for a cervical neoplasia.

Carbonic Anhydrase IX References

Carbonic Anhydrase IX Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Lutetium-177 DOTA girentuximab Phase 2 Clinical Telix Pharmaceuticals, Heidelberg, Wilex Carcinoma, Renal Cell Details
PMI-05 PMI-05 Phase 1 Clinical Precision Molecular Neoplasms Details
Sulfamide-nitroimidazole Clinical Dualtpharma Neoplasms Details
Indium-111-DOTA-girentuximab-IRDye800CW (Radboud University) Phase 1 Clinical Radboud University Nijmegen Carcinoma, Renal Cell; Diagnostic agents Details

This web search service is supported by Google Inc.

totop